Please ensure Javascript is enabled for purposes of website accessibility

3 Healthcare Stocks With Solid Dividends to Hold Through Bumpy Times

By Jim Halley - Apr 29, 2020 at 6:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Johnson & Johnson, AbbVie, and GlaxoSmithKline are all good choices.

As the coronavirus pandemic continues, investors from every part of the spectrum are looking for safe, stable companies to rely on -- and a nice dividend doesn't hurt. Here are three great healthcare stocks whose dividends are the cherry on top of a great operation. 

Start with Johnson & Johnson, the gold standard of healthcare dividend stocks

I love Johnson & Johnson (JNJ 0.29%) as a healthcare dividend giant. It's a diversified company that is built to handle anything thrown at it: lawsuits, pandemic shutdown, zombie apocalypse, whatever.

It's almost as if Johnson & Johnson is an alternate universe, one where pandemics don't seem to matter too much. 

The company's first-quarter 2020 numbers, released April 14, show a 3.3% increase in sales (compared with the same quarter a year ago) and a 54.6% rise in net earnings. Its consumer health and pharmaceutical divisions saw 9.2% and 8.7% increases in sales, respectively. The only group where sales slowed was medical devices, which dropped 8.2%. 

Doctor with stethoscope

Image Source: Getty Images.

Johnson & Johnson is also working with Emergent Biosolutions on a contract to help manufacture a vaccine to treat COVID-19.

The company has increased quarterly dividends for 58 years and this month announced it was raising the second-quarter dividend to $1.01 a share, an increase of 6.3% from the first quarter and a solid yield of 2.62% (above the S&P's average yield of about 2%). The only downside is that Johnson & Johnson's dividend yield is more conservative than some other healthcare stocks.  

AbbVie is much more than Humira 

Pharmaceutical giant AbbVie (ABBV -0.64%) may only have been around since 2013, but that's not stopping it from making money: The company boasted 2019 full-year net revenue of $33.3 billion. About $14.8 billion of that came from its star biologic drug, Humira, but the company expects that number to drop with more biosimilar competition to the drug in Europe and, in 2023, in the United States. 

But AbbVie has diversified its drug pipeline well beyond Humira, Two drugs, in particular, stand out after launches last year: Skyrizi, which treats moderate to severe plaque psoriasis in adults, brought in net revenue of $355 million , and Rinvoq, which treats rheumatoid arthritis, brought in $47 million.  

AbbVie's acquisition of Allergan, which is likely to be finalized soon, will add to the company's balance sheet and pipeline -- Allergan brings with it drugs including Vraylar (for schizophrenia), Botox and Juvederm (for skin), and Restasis (eye drops). AbbVie's dividend offers a 5.51% annual yield, and the stock is well priced, with a P/E ratio of 16 and a stock price well below its 52-week high of $97.86. Its first-quarter results are due May 1.

The company predicted stand-alone revenue growth on an operational basis of 8% in 2020. That guidance was issued before the pandemic shutdown, but it shows AbbVie is likely in solid shape to have another strong year. 

GlaxoSmithKline has its eye on the future

GlaxoSmithKline (GSK -0.55%) has given its investors a little heartache of late, falling to a 52-week low of $31.43 per share on March 23. It has since rebounded more than 36%. The most positive recent news from the company came on April 14, when it announced it was working with Sanofi (SNY -5.01%) on a COVID-19 vaccine. And GlaxoSmithKline's dividend yield of 4.73% makes up for any short-term bumps; in fact, it just increased its dividend 21%, to $0.567 a share .

First-quarter results are expected today, and the company has said it expects sales to be slightly down, as decreases in the sales of its established drugs won't be completely made up for by increased sales of its newer drugs. That's not surprising, considering what happened with the world economy during the first quarter; what's notable is that the decline is expected to be slight, showing the essential strength of large healthcare companies with a diversified pharmaceutical pipeline, such as GlaxoSmithKline. 

One particular area to watch for GlaxoSmithKline is its stable of new oncology drugs, including belantamab mafodotin, used to treat multiple myeloma (a type of blood cancer), and Zejula, used to treat ovarian cancer. Some of the newer drugs that increased sales last year included Shingrix, a shingles vaccine ($2.3 billion in 2019); Trelegy Ellipta, used to treat a wealth of chronic obstructive pulmonary disease (COPD) symptoms ($642 million); and Juluca, used to fight HIV ($455 million). The company has said it could have as many as six new drugs this year in its oncology, HIV, specialty and respiratory divisions. 

Two threads connect all three stocks

All of these stocks have the growth you might expect from a healthcare stock, and because of their strong dividends, they also offer the safety investors may be looking for during a turbulent time in the market. If I had to pick, I'd go with AbbVie, because its short-term business looks as solid as its long-term outlook and it has the best yield of the three. If you're purely looking for safety, Johnson & Johnson is your best bet. Investors will want to wait on GlaxoSmithKline's first-quarter earnings before jumping in. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$177.51 (0.29%) $0.52
GSK Stock Quote
GSK
GSK
$43.53 (-0.55%) $0.24
AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$153.16 (-0.64%) $0.98
Sanofi Stock Quote
Sanofi
SNY
$50.03 (-5.01%) $-2.64
Allergan plc Stock Quote
Allergan plc
AGN
Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$31.04 (1.67%) $0.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.